Par Sterile Products patents expiration
1. Adrenalin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9119876 | PAR STERILE PRODUCTS | Epinephrine formulations |
Mar, 2035
(10 years from now) | |
| US10130592 | PAR STERILE PRODUCTS | Epinephrine formulations |
Mar, 2035
(10 years from now) | |
| US9295657 | PAR STERILE PRODUCTS | Epinephrine formulations |
Mar, 2035
(10 years from now) | |
| US11083698 | PAR STERILE PRODUCTS | Epinephrine compositions and containers |
Mar, 2039
(14 years from now) | |
| US11207280 | PAR STERILE PRODUCTS | Epinephrine compositions and containers |
Mar, 2039
(14 years from now) | |
| US10653646 | PAR STERILE PRODUCTS | Epinephrine compositions and containers |
Mar, 2039
(14 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 18 December, 2013
Treatment: Emergency treatment of allergic reactions (type i), including anaphylaxis; To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock
Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS; SOLUTION;INTRAVENOUS
ADRENALIN family patents
2. Vasostrict patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9919026 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9375478 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9687526 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9974827 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9968649 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9962422 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9925234 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9925233 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9981006 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US10010575 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9750785 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9744209 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9744239 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
| US9937223 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
Drugs and Companies using VASOPRESSIN ingredient
Market Authorisation Date: 17 April, 2014
Treatment: To increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines
Dosage: SOLUTION;INTRAVENOUS
VASOSTRICT family patents